WellSpan Health – Innovations & Advancements in Cancer Treatment
John Grim's doctor and Medical Director of Radiation Oncology at WellSpan Health, Dr. Navesh Sharma, spoke with Amy about Pluvicto, new cancer treatments being offered at WellSpan Health, Proton Therapy, and more.
As part of today's special Good Day PA, abc27 and WellSpan Health hosted a live webchat. Dr. Jaganmohan Poli, Radiation Oncologist at WellSpan Health, answered viewer submitted questions about radiation oncology and radiation therapy.
Amy spoke with Dr. Scott Tiedbohl, Thoracic Surgeon at WellSpan Health, to learn more about lung cancer screening, advancements in technology and treatments, and how these benefit patients and the community.
WellSpan Cancer Institute is proud of it's efforts to truly listen to patients, allowing experts to customize treatment options while offering compassionate care. Amy spoke with Dr. Nik Korgaonkar to learn more.
Dr. Poli joined Janel again later in the show to answer more viewer questions.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
a day ago
- Medscape
Pluvicto vs ARPI in Prostate Cancer: Is One Better?
TOPLINE: Patients with metastatic castration-resistant prostate cancer who received Lu-177-PSMA-617 (Pluvicto) achieved similar overall survival and had fewer serious adverse events compared to those who switched androgen receptor pathway inhibitors (ARPI) after progressing on a first-line ARPI. However, the authors noted, the overall survival results "were likely confounded by the high rate of crossover" from a second-line ARPI to Lu-177-PSMA-617. METHODOLOGY: Patients with metastatic castration-resistant prostate cancer who progress on first-line ARPI therapy and are taxane-naive may receive an ARPI in the second-line setting if they are unable to tolerate taxane-based chemotherapy. However, an ARPI is not the most active treatment in this setting. In the PSMAfore trial , researchers compared the efficacy of another agent — Lu-177-PSMA-617 — to an ARPI as a second-line treatment option. Overall, 468 patients with PSMA-positive metastatic castration-resistant prostate cancer were randomly assigned to receive either Lu-177-PSMA-617 (n = 234) or ARPI switch (n = 234). Participants had previously experienced disease progression on an ARPI (abiraterone, enzalutamide, darolutamide, or apalutamide) and were deemed appropriate to delay taxane-based chemotherapy. Participants received Lu-177-PSMA-617 at a dose of 7.4 GBq once every 6 weeks for six cycles or ARPI change (abiraterone or enzalutamide at the treating physician's discretion). Patients in the ARPI arm could cross over to Lu-177-PSMA-617 after centrally confirmed radiographic progression. In the initial analysis, radiographic progression-free survival appeared longer in patients receiving Lu-177-PSMA-617 compared to a second-line ARPI. During the final analysis , 60.3% of participants (141 of 234) randomly assigned to the ARPI switch group crossed over to receive Lu-177-PSMA-617, representing 75.4% of patients with confirmed radiographic progression. The median duration of exposure was 8.41 months in the Lu-177-PSMA-617 arm, 6.54 months in the ARPI-change arm, and 7.16 months in the crossover group. TAKEAWAY: Median overall survival was similar in both groups: 24.48 months with Lu-177-PSMA-617 vs 23.13 months with ARPI change (hazard ratio [HR], 0.91; P = .20), according to the intention-to-treat analysis. In a crossover-adjusted analysis, patients receiving Lu-177-PSMA-617 demonstrated a significant survival benefit (HR, 0.59), which "suggested that treatment crossover likely confounded [overall survival]," the authors wrote. Treatment-emergent adverse events of grade 3 or higher were lower in the Lu-177-PSMA-617 group, as were rates of serious adverse events of any grade. In the Lu-177-PSMA-617 arm, more common adverse events included dry mouth and anemia. Dry mouth of any grade occurred in nearly 60% of participants, with less than 1% experiencing events of grade 3 or higher. Anemia of any grade occurred in about 27% of patients, with 6.2% experiencing events of grade 3 or higher. These events were predominantly low grade and resolved or were resolving at the final analysis. IN PRACTICE: Taken together with the previous observations from PSMAfore, "these results further support 177Lu-PSMA-617 as an alternative treatment option to ARPI change" in this patient population, the authors wrote. SOURCE: The study, led by Karim Fizazi, PhD, Institut Gustave Roussy and Centre Oscar Lambret, Université Paris-Saclay in Villejuif, France, was published online in Annals of Oncology. LIMITATIONS: The high rate of crossover probably confounded the overall survival analysis. The study excluded patients with known genomic alterations, limiting generalizability. Additionally, the trial may have been underpowered to detect an overall survival difference between arms, a limitation further exacerbated by the high crossover rate. DISCLOSURES: This study was funded by Novartis. Four authors reported being employees of and receiving restricted stock options from Novartis. Several authors reported receiving research grants or honoraria and having other ties with various sources. Additional disclosures are noted in the original article. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Medscape
29-07-2025
- Medscape
Preterm Birth Predicts Adult Health Problems
Adults born preterm were significantly more likely to have cardiometabolic risk factors and internalized mental health issues than full-term peers, according to an ongoing preterm birth cohort study in the US. 'This study addresses a significant gap in understanding the long-term health effects of preterm birth in the US,' said lead author Amy D'Agata, PhD, of the College of Nursing, The University of Rhode Island, Kingston, Rhode Island, in an interview. Although the annual preterm birth rate in the US has held at a relatively stable 10%-12% for decades, since the 1970s, more preterm infants are surviving because of advances in neonatal intensive care, D'Agata said. Millions of individuals born preterm are aging into adulthood, but few data are available on their long-term health outcomes, she noted. In the new study, published in JAMA Network Open , D'Agata and colleagues reviewed data from a cohort of individuals who received level III neonatal intensive care at a single center between 1985 and 1989. The study population included 158 preterm-born and 55 full-term born adult control individuals. Preterm was defined as weighing under 1850 g at birth with various neonatal diagnoses; critically ill infants and those with major congenital abnormalities were excluded. The mean age across the groups was 35 years; 50% were women. The researchers used latent growth curve models to show changes over time. Overall, the preterm individuals who had higher medical risk in early life were significantly more likely to have a range of health problems at 35 years of age, notably, higher triglycerides than control individuals (beta value, 53.97; P = .03). Measures of systolic blood pressure and central adiposity also were significantly higher in the preterm birth group (beta values of 7.15 and 0.22, respectively), whereas bone density and high-density lipoprotein cholesterol were lower (beta values of -1.14 and -13.07, respectively). In addition, internalizing mental health problems were significantly more common in the preterm cohort than in the control individuals (beta value, 0.85; P = .01) but no difference in externalizing mental health problems was noted between the groups. The researchers also reviewed the impact of social protection and childhood socioeconomic status and found no association between these and physical or psychological health risks in adults born preterm. The Long View of Preterm Birth The population of adults born preterm remains largely invisible to the US healthcare system and its clinicians, highlighting critical issues of health equity and quality of care, D'Agata told Medscape Medical News . 'Much of the existing research in this area has focused on international, homogeneous populations, creating a need for rigorous, US-based longitudinal data to guide healthcare policy and clinical practice,' she added. 'These findings generally confirmed what has been observed internationally, that there is a link between higher early life medical risk and increased likelihood of mental health issues, elevated systolic blood pressure, unfavorable cholesterol and triglyceride levels, body fat distribution, and lower bone density among adults born preterm, and it was notable to see these clear and consistent associations replicated in a US cohort using a prospective, longitudinal design,' said D'Agata. The study findings emphasized the need to inquire about birth history in adult care settings and suggest that those born preterm and their families must be their own health advocates, if necessary, said D'Agata. 'Even if a patient isn't asked about their birth history, they should share it,' she noted. Clinicians work hard to provide the best care, but it takes time for evidence-based research to inform clinical practice, she said. 'Although our birth cohort is small and comes from a single geographic region, the results generally align with international findings,' D'Agata told Medscape Medical News . However, future studies should include more racially and ethnically diverse cohorts from multiple clinical settings, she said. Research is needed not only to examine which subgroups of preterm individuals are most at risk but also to differentiate between those with varying degrees of early life complications, she added. Long Follow-Up Strengthens Findings The 35-year duration of the preterm birth cohort study was impressive and valuable, said Tim Joos, MD, a clinician with a combination internal medicine/pediatrics practice at Neighborcare Health in Seattle. 'We don't often have the long game in mind, in healthcare as well as in other parts of our society,' said Joos, who was not involved in the study. 'We don't tend to follow pediatric conditions into adulthood,' he noted. The current study findings demonstrated a long-term psychological and physical impact of prematurity on adult health that was humbling, Joos told Medscape Medical News . Looking ahead, the results highlight not only the need to continue to prevent preterm birth but also to the importance of asking older patients about preterm birth as part of their health history, he said.
Yahoo
24-07-2025
- Yahoo
Market to Reach $10.2 Billion by 2030 - Surge in Awareness Campaigns on Early Cancer Detection Supports Growth
The Radiation Oncology market is propelled by advancements in precise, innovative therapies like IMRT and proton therapy, driven by rising global cancer incidences. Growing AI integration, personalized oncology, and adaptive radiotherapy enhance treatment efficacy. Emerging markets and infrastructure investments offer key growth opportunities. Radiation Oncology Market Dublin, July 24, 2025 (GLOBE NEWSWIRE) -- The "Radiation Oncology - Global Strategic Business Report" report has been added to global market for Radiation Oncology was estimated at US$7.9 Billion in 2024 and is projected to reach US$10.2 Billion by 2030, growing at a CAGR of 4.3% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The growth in the radiation oncology market is driven by several factors, including the global rise in cancer prevalence, advancements in radiotherapy technologies, and increasing healthcare investments in oncology infrastructure. Rising incidence of complex and treatment-resistant cancers is propelling demand for precision-focused modalities like proton therapy and stereotactic radiotherapy. At the same time, technological convergence between AI, imaging, and radiotherapy is facilitating personalized treatment planning and outcome monitoring, which enhances clinical effectiveness and operational funding and public-private partnerships are accelerating the deployment of radiotherapy infrastructure in both developed and emerging regions. Additionally, expanding insurance coverage for advanced radiotherapy procedures and increasing awareness about early cancer detection are supporting treatment uptake. Ongoing clinical trials exploring novel combinations of immunotherapy with radiation are expected to open new therapeutic frontiers in the years ahead. Together, these drivers are positioning radiation oncology not only as a cornerstone of modern cancer therapy but also as a field undergoing continuous technological and clinical innovation, with strong growth prospects globally. How Is Radiation Oncology Evolving in Response to Cancer Care Demands?Radiation oncology continues to be a cornerstone in the multidisciplinary management of cancer, with ongoing innovations enhancing both efficacy and precision in targeting malignant tissues. The field has shifted significantly from conventional radiotherapy to highly advanced techniques such as intensity-modulated radiation therapy (IMRT), stereotactic radiosurgery (SRS), image-guided radiation therapy (IGRT), and proton beam therapy. These modalities allow for accurate dose delivery that spares surrounding healthy tissue, reduces side effects, and improves patient outcomes. Growing cancer incidence worldwide, coupled with an aging population, is pushing healthcare systems to expand radiation oncology infrastructure and adoption of personalized oncology, where treatment is tailored based on tumor genetics and radiomic data, is further redefining treatment planning. Integration of artificial intelligence and machine learning algorithms into radiation oncology software is facilitating adaptive radiotherapy, which adjusts treatment in real time based on patient response and anatomical changes. Additionally, advancements in radiobiology and hypofractionation protocols are enabling shorter treatment durations with equal or improved efficacy, enhancing both throughput and patient convenience. These developments are driving clinical and operational transformation in radiation oncology centers Technologies and Modalities Are Shaping Modern Radiation Oncology Practice?Cutting-edge technologies are transforming the landscape of radiation oncology, with linear accelerators (LINACs), proton therapy units, brachytherapy equipment, and robotic radiosurgery platforms gaining prominence. LINAC systems now incorporate multi-leaf collimators (MLCs), volumetric modulated arc therapy (VMAT), and onboard imaging to deliver precise tumor targeting in fewer sessions. Proton therapy, which deposits most of its energy at the Bragg peak, is witnessing rapid adoption in pediatric oncology and complex tumor cases due to its minimal collateral damage and reduced long-term motion management techniques such as respiratory gating and real-time tumor tracking are being incorporated to address organ movement during therapy, particularly in lung and gastrointestinal cancers. Brachytherapy is gaining renewed interest for cervical, prostate, and breast cancers, thanks to its high dose localization and shortened treatment duration. Integration of MRI and PET imaging into planning systems enhances tumor delineation and adaptive treatment planning. Additionally, emerging radiopharmaceuticals in targeted radionuclide therapy are expanding treatment options for metastatic cancers, particularly in prostate and neuroendocrine Are Hospitals and Cancer Centers Adapting to the Radiation Oncology Revolution?Radiation oncology departments are undergoing significant upgrades to accommodate new technologies, workflow automation, and multidisciplinary integration. Hospitals are investing in hybrid operating suites, advanced treatment planning software, and oncology information systems (OIS) to streamline patient data management and outcome tracking. Additionally, collaborations between radiation oncologists, medical physicists, dosimetrists, and IT professionals are being formalized into cross-functional teams to optimize treatment planning and delivery. Academic medical centers are leading the charge in deploying AI-guided adaptive planning tools and cloud-based contouring platforms that enhance precision while reducing planning and workforce development are also critical components of adaptation. The complexity of modern radiotherapy requires constant upskilling in areas such as image interpretation, machine calibration, and cybersecurity for networked oncology systems. Moreover, hospitals are adopting patient-centered models that integrate psychosocial support, symptom tracking, and remote consultations into radiation oncology care pathways. Global oncology networks and tele-radiation platforms are helping extend advanced radiotherapy services to underserved regions, reducing disparities in cancer treatment access. These operational and clinical upgrades are central to radiation oncology's evolution from a procedural specialty into a fully integrated, data-driven care model. Why You Should Buy This Report: Detailed Market Analysis: Access a thorough analysis of the Global Radiation Oncology Market, covering all major geographic regions and market segments. Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies. Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Radiation Oncology Market. Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions. Key Insights: Market Growth: Understand the significant growth trajectory of the External Beam Radiation Therapy segment, which is expected to reach US$3.6 Billion by 2030 with a CAGR of a 3.3%. The Brachytherapy segment is also set to grow at 5.5% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, estimated at $2.2 Billion in 2024, and China, forecasted to grow at an impressive 7.6% CAGR to reach $2.1 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Report Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of players such as Accuray Incorporated, Bionix Radiation Therapy, LLC, Brainlab AG, Canon Medical Systems Corporation, Curium and more. Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments. Scope of Study: Treatment Type (External Beam Radiation Therapy, Brachytherapy, Systemic Radiation Therapy, Stereotactic Radiosurgery) Technology (Linear Accelerators Technology, Radioisotopes Technology, Particle Therapy Technology, Tomotherapy Technology) Application (Breast Cancer Application, Prostate Cancer Application, Lung Cancer Application, Brain Cancer Application, Head & Neck Cancer Application) End-Use (Hospitals End-Use, Outpatient Clinics End-Use, Cancer Research Institutes End-Use, Ambulatory Surgery Centers End-Use) Key Attributes: Report Attribute Details No. of Pages 488 Forecast Period 2024 - 2030 Estimated Market Value in 2024 7.9 Billion Forecasted Market Value by 2030 10.2 Billion Compound Annual Growth Rate 4.3% Regions Covered Global Key Topics Covered: MARKET OVERVIEW Influencer Market Insights World Market Trajectories Tariff Impact on Global Supply Chain Patterns Radiation Oncology - Global Key Competitors Percentage Market Share in 2025 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E) MARKET TRENDS & DRIVERS Rising Cancer Incidence Worldwide Throws the Spotlight on Advanced Radiotherapy Modalities Technological Advancements in Image-Guided Radiation Therapy Strengthen Precision Treatment Capabilities Expansion of Linear Accelerator Installations in Emerging Markets Drives Equipment Uptake Integration of Artificial Intelligence in Treatment Planning Accelerates Adoption of Adaptive Therapy Solutions Rising Utilization of Stereotactic Radiosurgery Expands Clinical Applications in Brain and Spine Tumors Growth in Proton and Heavy Ion Therapy Centers Drives Demand for High-End Oncology Infrastructure Collaborations Between Research Institutions and Hospitals Fuel Personalized Oncology Approaches Favorable Reimbursement Policies for Radiation Oncology Procedures Sustain Market Accessibility Growing Adoption of Hypofractionated Radiotherapy Enhances Patient Convenience and Throughput Emergence of Real-Time Tumor Tracking and Motion Management Improves Clinical Outcomes Rising Investments in Hybrid Radiotherapy Systems Strengthen Business Case for Multi-Modality Platforms Expansion of Cancer Care Networks and Outreach Programs Boosts Regional Equipment Penetration Increased Focus on Pediatric Radiation Safety Drives Innovation in Dose Optimization Tools Partnerships With Academic Medical Centers Accelerate Development of Evidence-Based Protocols Government Grants for Cancer Treatment Infrastructure Upgrade Promote Public Hospital Modernization Shift Toward Outpatient Radiotherapy Centers Enhances Equipment Turnaround and Affordability Development of Cloud-Based Treatment Planning Systems Improves Workflow and Collaboration Integration of Immunotherapy and Radiotherapy Approaches Strengthens Clinical Trial Pipelines Surge in Awareness Campaigns on Early Cancer Detection Supports Radiation Oncology Growth AI-Enabled Radiomics and Predictive Modeling Drive Precision Medicine in Radiation Treatment FOCUS ON SELECT PLAYERS |Some of the 44 companies featured in this Radiation Oncology market report include: Accuray Incorporated Bionix Radiation Therapy, LLC Brainlab AG Canon Medical Systems Corporation Curium Eckert & Ziegler BEBIG Elekta AB GE Healthcare Hitachi Ltd. IBA (Ion Beam Applications SA) Isoray Inc. Mevion Medical Systems Inc. Nanobiotix Nordion Inc. Optivus Proton Therapy Inc. Panacea Medical Technologies Pvt. Ltd. RefleXion Medical RaySearch Laboratories AB Siemens Healthineers AG Sirtex Medical Limited Varian Medical Systems (Siemens) ViewRay Technologies, Inc. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Radiation Oncology Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
